<DOC>
	<DOCNO>NCT02202408</DOCNO>
	<brief_summary>In Phase I study , primary objective investigate safety tolerability SKI2670 oral administration healthy female subject . And secondary objective investigate pharmacokinetics pharmacodynamics SKI2670 oral administration healthy female subject .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetic Pharmacodynamic Study SKI2670</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<criteria>1 . Female , 20 year age old 2 . Weight 40kg~70kg 3 . Women agree use double contraception method spermicide , avoid breastfeed least 30days IP ( investigational product ) dose 4 . A history regular menstrual cycle ( cycle : 28±7day , duration : 2~7day ) least 2 year positive ovulation test day 11 21 precede menstrual cycle IP ( investigational product ) dose 1 . Women pregnant serum/urine hCG ( human chorionic gonadotropin ) positive breastfeed 2 . A history breast cancer , genital cancer estrogen dependent tumor 3 . Specified unspecified diagnosed infertility history natural abortion three time 4 . A history take Investigational product within 60days screen visit take ETC drug ( Ethical drug ) , oriental medicine OTC drug ( OvertheCounter drug ) within 14days screen visit 5 . Clinically significant Gynecological disease identify ultrasonography include estrogen dependent tumor lesion , sever inflammation synechia 6 . AST ( Aspartate aminotransferase ) , ALT ( Alanine aminotransferase ) ≥ 2.5 time upper limit normal 7 . QTc &gt; 450ms electrocardiogram result</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>